Increased expression of CD11b/CD18 on phagocytes in ischaemic disease: A bridge between inflammation and coagulation

A. Mazzone, S. De Servi, I. Mazzucchelli, G. Fossati, D. Gritti, C. Canale, C. Cusa, G. Ricevuti

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The aim of this study was to assess the expression of CD11b/CD18 integrin adhesion molecules on the phagocytes of patients with ischaemic diseases, and to evaluate the concentration of soluble adhesion molecules that are released from endothelium (sICAM-1) and from phagocytes (sL- selectin). A total of 370 patients were enrolled: 120 with coronary artery disease (CAD); 50 with peripheral artery occlusive disease (PAOD); and 200 control subjects with no clinical manifestations of ischaemic disease. CD11b/CD18 integrin was detected by flow cytometry, whereas sL-selectin and sICAM-1 concentrations were detected using a sandwich-type immunoassay. CD11b/CD18 integrin expression was found to be higher in the patients with ischaemic disease than in the control subjects (P <0.001). The PAOD patients had higher values of CD11b/CD18 integrin than the CAD ones (P <0.01). The concentration of soluble adhesion molecules did not show any significant differences within the three groups (P = NS). The high expression of CD11b/CD18 integrin in ischaemic disease patients may depend on the increased, but probably stable, cytokine network that has been demonstrated to occur in chronic ischaemic diseases: the difference observed between PAOD and CAD patients could be the consequence of higher inflammatory activation probably resulting from the greater extent of the atherosclerotic process in PAOD, or of the more localized ischaemic area in CAD patients. CD11b/CD18 can therefore be considered a marker of chronic: phagocyte activation during ischaemic disease. On the other hand, sICAM and sL-selectin concentrations were found to be within the normal range; they have recently been considered as a marker for acute ischaemic events and acute inflammatory process activation. Our results confirm that in uncomplicated atherosclerosis no acute inflammatory process activation should occur.

Original languageEnglish
Pages (from-to)648-652
Number of pages5
JournalEuropean Journal of Clinical Investigation
Volume27
Issue number8
Publication statusPublished - 1997

Fingerprint

Phagocytes
Coagulation
Integrins
Inflammation
Peripheral Arterial Disease
Selectins
Coronary Artery Disease
Chemical activation
Adhesion
Immunoassay
Molecules
Endothelium
Atherosclerosis
Flow Cytometry
Reference Values
Chronic Disease
Cytokines
Flow cytometry

Keywords

  • Coronary artery disease
  • Integrins
  • Peripheral artery occlusive disease
  • Phagocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Increased expression of CD11b/CD18 on phagocytes in ischaemic disease : A bridge between inflammation and coagulation. / Mazzone, A.; De Servi, S.; Mazzucchelli, I.; Fossati, G.; Gritti, D.; Canale, C.; Cusa, C.; Ricevuti, G.

In: European Journal of Clinical Investigation, Vol. 27, No. 8, 1997, p. 648-652.

Research output: Contribution to journalArticle

Mazzone, A, De Servi, S, Mazzucchelli, I, Fossati, G, Gritti, D, Canale, C, Cusa, C & Ricevuti, G 1997, 'Increased expression of CD11b/CD18 on phagocytes in ischaemic disease: A bridge between inflammation and coagulation', European Journal of Clinical Investigation, vol. 27, no. 8, pp. 648-652.
Mazzone, A. ; De Servi, S. ; Mazzucchelli, I. ; Fossati, G. ; Gritti, D. ; Canale, C. ; Cusa, C. ; Ricevuti, G. / Increased expression of CD11b/CD18 on phagocytes in ischaemic disease : A bridge between inflammation and coagulation. In: European Journal of Clinical Investigation. 1997 ; Vol. 27, No. 8. pp. 648-652.
@article{03ed0db91f694589925f699cd556b2dc,
title = "Increased expression of CD11b/CD18 on phagocytes in ischaemic disease: A bridge between inflammation and coagulation",
abstract = "The aim of this study was to assess the expression of CD11b/CD18 integrin adhesion molecules on the phagocytes of patients with ischaemic diseases, and to evaluate the concentration of soluble adhesion molecules that are released from endothelium (sICAM-1) and from phagocytes (sL- selectin). A total of 370 patients were enrolled: 120 with coronary artery disease (CAD); 50 with peripheral artery occlusive disease (PAOD); and 200 control subjects with no clinical manifestations of ischaemic disease. CD11b/CD18 integrin was detected by flow cytometry, whereas sL-selectin and sICAM-1 concentrations were detected using a sandwich-type immunoassay. CD11b/CD18 integrin expression was found to be higher in the patients with ischaemic disease than in the control subjects (P <0.001). The PAOD patients had higher values of CD11b/CD18 integrin than the CAD ones (P <0.01). The concentration of soluble adhesion molecules did not show any significant differences within the three groups (P = NS). The high expression of CD11b/CD18 integrin in ischaemic disease patients may depend on the increased, but probably stable, cytokine network that has been demonstrated to occur in chronic ischaemic diseases: the difference observed between PAOD and CAD patients could be the consequence of higher inflammatory activation probably resulting from the greater extent of the atherosclerotic process in PAOD, or of the more localized ischaemic area in CAD patients. CD11b/CD18 can therefore be considered a marker of chronic: phagocyte activation during ischaemic disease. On the other hand, sICAM and sL-selectin concentrations were found to be within the normal range; they have recently been considered as a marker for acute ischaemic events and acute inflammatory process activation. Our results confirm that in uncomplicated atherosclerosis no acute inflammatory process activation should occur.",
keywords = "Coronary artery disease, Integrins, Peripheral artery occlusive disease, Phagocytes",
author = "A. Mazzone and {De Servi}, S. and I. Mazzucchelli and G. Fossati and D. Gritti and C. Canale and C. Cusa and G. Ricevuti",
year = "1997",
language = "English",
volume = "27",
pages = "648--652",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Blackwell Publishing Ltd",
number = "8",

}

TY - JOUR

T1 - Increased expression of CD11b/CD18 on phagocytes in ischaemic disease

T2 - A bridge between inflammation and coagulation

AU - Mazzone, A.

AU - De Servi, S.

AU - Mazzucchelli, I.

AU - Fossati, G.

AU - Gritti, D.

AU - Canale, C.

AU - Cusa, C.

AU - Ricevuti, G.

PY - 1997

Y1 - 1997

N2 - The aim of this study was to assess the expression of CD11b/CD18 integrin adhesion molecules on the phagocytes of patients with ischaemic diseases, and to evaluate the concentration of soluble adhesion molecules that are released from endothelium (sICAM-1) and from phagocytes (sL- selectin). A total of 370 patients were enrolled: 120 with coronary artery disease (CAD); 50 with peripheral artery occlusive disease (PAOD); and 200 control subjects with no clinical manifestations of ischaemic disease. CD11b/CD18 integrin was detected by flow cytometry, whereas sL-selectin and sICAM-1 concentrations were detected using a sandwich-type immunoassay. CD11b/CD18 integrin expression was found to be higher in the patients with ischaemic disease than in the control subjects (P <0.001). The PAOD patients had higher values of CD11b/CD18 integrin than the CAD ones (P <0.01). The concentration of soluble adhesion molecules did not show any significant differences within the three groups (P = NS). The high expression of CD11b/CD18 integrin in ischaemic disease patients may depend on the increased, but probably stable, cytokine network that has been demonstrated to occur in chronic ischaemic diseases: the difference observed between PAOD and CAD patients could be the consequence of higher inflammatory activation probably resulting from the greater extent of the atherosclerotic process in PAOD, or of the more localized ischaemic area in CAD patients. CD11b/CD18 can therefore be considered a marker of chronic: phagocyte activation during ischaemic disease. On the other hand, sICAM and sL-selectin concentrations were found to be within the normal range; they have recently been considered as a marker for acute ischaemic events and acute inflammatory process activation. Our results confirm that in uncomplicated atherosclerosis no acute inflammatory process activation should occur.

AB - The aim of this study was to assess the expression of CD11b/CD18 integrin adhesion molecules on the phagocytes of patients with ischaemic diseases, and to evaluate the concentration of soluble adhesion molecules that are released from endothelium (sICAM-1) and from phagocytes (sL- selectin). A total of 370 patients were enrolled: 120 with coronary artery disease (CAD); 50 with peripheral artery occlusive disease (PAOD); and 200 control subjects with no clinical manifestations of ischaemic disease. CD11b/CD18 integrin was detected by flow cytometry, whereas sL-selectin and sICAM-1 concentrations were detected using a sandwich-type immunoassay. CD11b/CD18 integrin expression was found to be higher in the patients with ischaemic disease than in the control subjects (P <0.001). The PAOD patients had higher values of CD11b/CD18 integrin than the CAD ones (P <0.01). The concentration of soluble adhesion molecules did not show any significant differences within the three groups (P = NS). The high expression of CD11b/CD18 integrin in ischaemic disease patients may depend on the increased, but probably stable, cytokine network that has been demonstrated to occur in chronic ischaemic diseases: the difference observed between PAOD and CAD patients could be the consequence of higher inflammatory activation probably resulting from the greater extent of the atherosclerotic process in PAOD, or of the more localized ischaemic area in CAD patients. CD11b/CD18 can therefore be considered a marker of chronic: phagocyte activation during ischaemic disease. On the other hand, sICAM and sL-selectin concentrations were found to be within the normal range; they have recently been considered as a marker for acute ischaemic events and acute inflammatory process activation. Our results confirm that in uncomplicated atherosclerosis no acute inflammatory process activation should occur.

KW - Coronary artery disease

KW - Integrins

KW - Peripheral artery occlusive disease

KW - Phagocytes

UR - http://www.scopus.com/inward/record.url?scp=0030840492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030840492&partnerID=8YFLogxK

M3 - Article

C2 - 9279527

AN - SCOPUS:0030840492

VL - 27

SP - 648

EP - 652

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 8

ER -